A team at LMU Munich has built what it describes as the first human cell model that reproduces the tau pathology underlying Alzheimer's disease and frontotemporal dementia. Working in the lab of Professor Dominik Paquet at the Institute for Stroke and Dementia Research, first author Dr. Angelika Dannert used CRISPR/Cas9 to alter human neurons so that they produce the adult form of the tau protein and carry disease-causing mutations. Left to develop, the cells went on to form tau aggregates closely resembling the tangles seen in the brains of people with these diseases, along with signs of neuronal injury such as loss of synapses.
The technical detail matters more than it might sound. Tauopathies remain incurable in part because researchers have lacked realistic systems in which to study how the disease actually unfolds. Animal models only approximate what happens in a human brain, and neurons grown from stem cells have tended to make the early, immature forms of tau found in very young brains rather than the adult variants that drive disease. By engineering neurons to produce the adult isoform, the LMU team removed a mismatch that has quietly limited this field for years.
The model is already being put to work. According to Dannert, a compound currently in clinical testing significantly reduced tau pathology in the engineered cells, and the team also validated an imaging biomarker used to diagnose certain tauopathies. That combination - a platform where candidate drugs and diagnostic tools can both be assessed in human cells showing genuine tau deposits - is what makes the system useful beyond basic biology.
Paquet frames the work as closing the gap between animal experiments and human disease, offering a new platform for developing and testing dementia therapies. This is laboratory research, not a treatment, and any compound that looks promising in engineered neurons still has to prove itself in patients. But better models tend to precede better drugs, and this one gives researchers their first chance to examine pathological tau structures in human cells under conditions that resemble the real thing.